ITOS News and Press, iTeos Therapeutics Inc. From 11/10/21

- First patients dosed in clinical trial of anti-TIGIT monoclonal antibody, EOS-448, in combination with pembrolizumab and with inupadenant in patients with solid tumors - Advanced clinical development of inupadenant, EOS-850, an A 2A receptor antagonist, with initia...

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 03, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, tod...

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Sept. 01, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immune-oncology therapeutics for patients, to...

iTeos Therapeutics had a cash balance of about $26.40 per share as of June 30, 2021. iTeos Therapeutics received a non-refundable upfront payment from GlaxoSmithKline representing revenue of approximately $17.80 per share. The payment is non-refundable and no additional performanc...

iTeos Therapeutics Inc. (ITOS) Q2 2021 Earnings Conference Call August 12, 2021 8:00 AM ET Company Participants Ryan Baker – Head-Investor Relations Michel Detheux – President and Chief Executive Officer Matthew Gall – Chief Financial Officer Joe Lager – Chief Medi...

Announced co-development and co-commercialization collaboration with GSK for anti-TIGIT monoclonal antibody EOS-448 (GSK’859); $625MM upfront payment in addition to $1.45B in potential milestones, 40/60 cost-sharing of global development, 50/50 profit share in the US, and royalty...

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Aug. 05, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, tod...

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Aug. 03, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, tod...

gguy44/iStock via Getty Images Piper Sandler Technical Market Strategist Craig. W. Johnson issued his July Alpha Alignment Report, which screens 900 stocks for a host of fundamental and technical factors. Along with the headline Alpha Alignment Index, the report also screens for an equal-weig...

CAMBRIDGE, Mass. and GOSSELIES, Belgium, July 08, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, tod...